

# The Concentration of Japanese Encephalitis Virus by Cross-Flow Ultrafiltration

洪淑甘、顏裕鴻

E-mail: 9708288@mail.dyu.edu.tw

## ABSTRACT

Japanese encephalitis virus (JEV) is an epidemic disease occurring not only in Japan but also in other countries in Asia. About 50,000 cases have been reported per year in these area and the number is increasing. The fatality rate is about 30% and 50% of those who survive develop neurological sequelae. Vero cell line was adapted from adult African green monkey kidney cell by Yasumura and Kawakita in 1962. JEV was isolated from Beijine strain in Japan. These cell lines are used in Rabies and Poliomyelitis vaccines at present and certified with safety. In this experiment, Vero cells were first grown in T-flask and then transferred to Roller bottle. The Beijine strain of JEV was inoculated the cell population reached to required density. The culture cells were harvested at 72hr. The harvested cells were then used for setting optimal cassette operating condition. Two 100kD cassettes of 50cm<sup>2</sup> and 0.02m<sup>2</sup> membrane area were evaluated with the condition of 4,2,0 and 6,0,0 psi. These two cassettes were compared for their efficacy at TMP 3psi. The comparison data between 4,2,0 psi (TMP 3psi) and 6,0,0 psi (TMP 3psi) showed that although flow rate was unstable with 4,2,0 psi (TMP 3psi), it performed higher recovery.

Keywords : Vero cell ; 100kD cassette ; Japanese encephalitis virus

## Table of Contents

目錄 封面內頁 簽名頁 授權書iii 中文摘要iv 英文摘要v 誌謝vi 目錄vii 圖目錄ix 表目錄xi 第一章 前言1 第二章 文獻回顧2 第一節 日本腦炎疫苗之介紹2 第二節 細胞培養4 第三節 病毒濃縮與蛋白質分析6 一、堆膜濃縮6 二、蛋白質定9 第三章 材料與方法16 第一節 實驗材料16 一、材料與藥品16 二、儀器設備17 第二節 實驗方法18 一、細胞培養18 二、病毒培養19 三、濃縮儀器設備安裝19 四、堆膜沖水及洗淨19 五、清水通透率之測定20 六、病毒樣品濃縮20 七、洗淨回復性確認20 八、堆膜使用後保存21 九、總蛋白質分析21 十、SDS-PAGE蛋白質電泳/銀染26 第四章 結果與討論29 第一節 壓力與流速之間的關係29 第二節 壓力與總蛋白質回收率的關係32 第三節 SDS-PAGE 蛋白質電泳/銀染32 第四節 蛋白質定量分析41 第五章 結論53 參考文獻54 圖目錄 圖2.1切向流堆膜過濾系統方式10 圖2.2壓濾(傳統方式)11 圖3.1清水通透率22 圖3.2樣品濃縮圖25 圖4.1壓力與流速之間的關係30 圖4.2100K50cm<sup>2</sup>堆膜卡匣壓力6.0.0 psi(TMP3psi)濃縮液與通透液的關係33 圖4.3100K50cm<sup>2</sup>堆膜卡匣壓力4.2.0 psi(TMP3psi)濃縮液與通透液的關係34 圖4.4100K0.02m<sup>2</sup>堆膜卡匣壓力6.0.0 psi(TMP3psi)濃縮液與通透液的關係35 圖4.5100K0.02m<sup>2</sup>堆膜卡匣壓力6.0.0 psi(TMP3psi)濃縮液與通透液的關係36 圖4.6SDS-PAGE/100K0.02m<sup>2</sup>堆膜卡匣壓力為6.0.0 psi(TMP3psi)39 圖4.7SDS-PAGE/100K0.02m<sup>2</sup>堆膜卡匣壓力為4.2.0 psi(TMP3psi)40 圖4.8病毒回收樣品經過0.8/0.2um過濾43 圖4.9堆膜卡匣濃縮後的樣品圖44 圖4.10緩衝液衝堤堆膜卡匣45 圖4.11通透液46 圖4.12堆膜卡匣濃縮後0.2um過濾前47 圖4.13病毒回收樣品0.8/0.2um過濾48 圖4.14病毒回收樣品經過0.8/0.2um過濾前49 圖4.15100K堆膜卡匣濃縮後的樣品50 圖4.16壓力4.2.0 psi ; TMP 3 psi 緩衝液沖洗堆膜卡匣51 圖4.17堆膜卡匣濃縮後0.2um過濾前52 表目錄 表2.1小孩1-14歲注射日本腦炎疫苗1、2、3及4劑量效價5 表2.2JEV病毒株7 表2.3BelloCell和microcarrier 培養vero cell生產日本腦炎疫苗8 表2.4millipore超過濾堆膜(UF membrane) 材質之選擇12 表2.5SDS-PAGE所需膠體之配製13 表2.6電解液:electrode buffer及樣品緩衝液配製sample buffer14 表2.7蛋白質分析干擾成分15 表3.1清水通透率計算(NWP)23 表3.2溫度校正係數表24 表4.1100K 50cm<sup>2</sup> 堆膜卡匣壓力為6.0.0 psi(TMP3psi)33 表4.2100K 50cm<sup>2</sup>堆膜卡匣壓力為4.2.0 psi(TMP3 psi)34 表4.3100K 0.02m<sup>2</sup>堆膜卡匣壓力為6.0.0 psi(TMP3psi)35 表4.4100K 0.02m<sup>2</sup>堆膜卡匣壓力為4.2.0 psi(TMP3psi)36 表4.5100K 50cm<sup>2</sup> 濃縮堆膜卡匣總蛋白質37 表4.6100K 0.02m<sup>2</sup>濃縮堆膜卡匣總蛋白質37

## REFERENCES

- 1.王秀智。2006。醣胺素與日本腦炎病毒之交互作用:12-13。國立清華大學生物資訊與結構生物研究所碩士論文。新竹,台灣。
- 2.江正榮、黃偉倫、鄒佩琪、廖明一。1997。日本腦炎病毒不活話劑之比較:138-145。行政院衛生署預防醫學研究所。研究年報。台北,台灣。
- 3.江政儒。2004。新穎性細胞貼附材質的開發,含醣胺素結合區之重組日本腦炎病毒蛋白:4-6。國立清華大學生命科學系碩士論文。新竹,台灣。
- 4.李淑英、陳國緯、廖美惠、廖明一。1997。組織培養日本腦炎疫苗菌種庫之建立:86-154。行政院衛生署預防醫學研究所。研究年報。台北,台灣。
- 5.李秉穎。1998。疫苗注射常見之問題及禁忌,台大醫院小兒部主治醫師。
- 6.吳夙欽、謝文欽、廖明一。1997。日本腦炎病毒發酵培養最適饋料策略之探討:109-118。行政院衛生署預防醫學研究所。研究年報。台北,台灣。
- 7.周如文,高

玉容, 林登藝, 1998。疫苗副作用及製造技術之研究改進:118-141。行政院衛生署預防醫學研究所。研究年報。台北, 台灣。8.許煒南。1994。蘇力菌多源、單元抗體之技術開發及應用:125-126。大葉工學院食品工程研究所碩士論文。彰化, 台灣。9.詹麗蓉、樂怡雲、吳盈昌、陳季幸、洪其璧、王躬仁。1998。日本腦炎病毒台灣分離株之基因差異性研究:141-154。行政院衛生署預防醫學研究所。研究年報。台北, 台灣。10.楊繼江。2001。病毒學概論。第3-293頁。藝軒圖書出版社。台北, 台灣。11.薛家倩。2004。SDS-PAGE蛋白質電泳分離技術:1-4。華文生技網。12.millipore。2000。框盒式切向流過濾系統。中文安裝、操作及維護手冊:4-37。13.millipore。2006。膜分離操作之最適化評估準則。TFF 使用者操作手冊:5-52。14.Abu, M., Kuzuhara, S., Kino, Y. 2003. Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells. *Vaccine*. 21:1989-1994. 15.Berry, J. M., Barnabe, N., Coombs, K. M., Butler, M. 1999. Production of reovirus type-1 and type-3 from Vero cell grown on solid and macroporous microcarriers. *Biochnol Bioeng*. 62:12-19. 16.Burke, D. S., Monath, T. P., Fields, Varology. 2001. 4th ed. Lippincott Philadelphia: 991-1055. 17.Chambers, T. J., Hahn, C. S., Galler, R., Rice, C. M. 1990. Flavivirus genome organization, expression and replication. *Ann Rev Microbiol*. 44:648-88. 18.Froud, S. J. 1999. The development, benefits and disadvantages of serum-free media, *Dev Biol Stand*. 99:57-66. 19.Hasegawa, H., Yoshida, M., Fujita, S. and Kobayashi, Y. 1994. Comparison of structural proteins among antigenically different Japanese encephalitis virus strains. *Vaccine*. 12:841-844. 20.Hiroko, Toriniwa. and Tomoyoshi, Komiya. 2007. Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor. *Biologicals*. 35:221-226. 21.Kitano, T., Yabe, S., Kobayashi, M., Oya, A. Ogata, T. 1986. Immunogenicity of JE Nakayama and Beijing-1 Vaccines. *JE & HFRS Bulletin*. p:37-41. 22.Konishi, E., Shoda, M. and Kondo, T. 2006. Analysis of yearly changes in levels of antibodies to Japanese encephalitis virus nonstructural 1 protein in racehorse in central Japan shows levels of natural virus activity still exist. *Vaccine*. 24:516-524. 23.Krmar, R., Mathur, A., Singh, K.B., Prasad, P.S.M., Shukla, R., Agarwal, S.P. 1993. 97:9-13. 24.Kurane, I., Takasaki, T. 2000. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. *Vaccine*. 18:33-35. 25.Lowry, O.H., and Bessey, O. A., J. 1946. *Biol.Chem.*, 163,633. 26.Mackenzie, J. S., Poidnger, M., Phillips, D. 1997. Emergence of Japanese encephalitis virus in the Australasian region, In: Saluzzo JF. Dodet B. editors. *Factors in the emergence of arbovirus diseases*. 191-201. 27.Mackenzie, J. S. 1999. The ecology Japanese encephalitis virus in the Australian region. *Clin Virol*. 27:1-17. 28.Mendonca, R. Z. Pereira, C. A. 1998. Cell metabolism and medium perfusion in Vero cell culture on microcarriers in a bioreactor. *Bioprocess Eng*. 18:213-218. 29.Mohan, Babu., Appaiagari and Sudhanshu, Vрати. 2004. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cell. *Vaccine*. 22:3669 – 675. 30. Monath, P. T., Myers, G. A., Beck, R. A., Knauber, M., Scappaticci, K., Pullano, T., Archambault, W. T., Catalan, J., Miller, C., Zhang, Z. X., Shin, S., Pugachev, K., Draper, K., Levenbook, I. S., Guirakhoo, F. 2005. Safety testing for neurovirulence of novel live. attenuated flavivirus vaccine: Infant mice provide an accurate surrogate for the test in monkeys. *Biologicals*. 33:131-144. 31.Montagnon, B. J., Vincent-Falquet, C. J. Saluzzo, J. F. 1999. Experience with Vero cell at Pasteur Merieux Connaught. *Dev Bioal Stand*. 98:137-140. 32.Montagnon, B. J.1989. Polio rabies vaccines produced in continuous cell line: a reality for vero cell line. *Develop. Biol. Standard* .70:27-47. 33.Montagnon, B. J., Fanget, B. Nicolas, A. J. 1981. The large-scale cultivation of Vero cell in microcarrier for virus vaccine production, Preliminary results for killed poliovirus vaccine. *Develop Biol Standard*. 47:55-64. 34.Nimmannitya, S., Hutamai, S., Kalayanarooj, S. Rojanasuphot, S. 1995. A field study on Nakayama and Beijing strain of Japanese encephalitis vaccines., *Southeast Asian J trop Med Public Health*. 26:689-93. 35.PALL. 2006. Membrane Cassette Care and Use Procedures. 6-29. 36.PIERCE. 2006BCA Protein Assay Kit # 23225. 1-7. 37.Poneprasert, B. 1989. Japanese encephalitis in children in northern Thailand, *Southeast Asian J Trop Med Pubic Health*. 20:599-603. 38.SIGMA. 2007. QuantiPro BCA Assay Kit. Product Code QP-BCA. 1-8. 39.Srivastava A., Putnak, J. R., Lee, S. H., Hong, S. P., Moon S B., Barvir D. A., Zhao B. Olson, R. A., Kim, S. O., Yoo, W. D., Towle A. D., Vaugh, D.W., Innis, B. L., Eckels, K.H. 2001. A purified inactivated Japanese encephalitis virus vaccine made in vero cells. *Vaccine*. 19:4557-4565. 40.Srivastava, A. K., Aira, Y., Mori, C. C., Kobayashi, Y., Igrashi, A. 1987. Antigenicity of Japanese encephalitis virus envelope glycoprotein V3 ( E ) and its cyanogens bromide cleaved fragments examined by monoclonal antibodies and Western blotting. *Arch Virol*. 96:96-107. 41.Sugawara., K., Nishiyama, K., Ishikawa, Y., Abu, M., Sonoda, K., Komatsu, K., Horikawa, Y., Takeda, K., Honda, T., Kuzuhara, S., Kino, Y. 2002. Development of Vero Cell-Derived Inactivated Japanese Encephalitis Vaccine. *Biological*. 30:303-314. 42.Sugawara, K., Nishiyama, K., Ishikawa, Y., Abu, M., Sonoda, K., Komatsu, K., Horikawa, Y., Takeda, K., Honda, T., Kuzuhara, S., Kino, Y., Mizokami, H., Mizuno, K., Oka, T., Honda K. 2002. Development of Vero Cell-Derived inactivated Japanese Encephalitis Vaccine. *Biologicals*. 30:303-314. 43.Sumiyoshi, H., Mori, C., Fuke, I., Morita, K., Kuhara, S., Kondou, J., Kikuchi, Y., Nagamatu, H., Igarashi, A. 1987. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. *Virology*. 161::497-510. 44.The National Institute of Health (eds) *Vaccine Handbook*. 1996. In: Researcher ' s Associates. Japanese encephalitis vaccine. Tokyo, Maruzen: 103-113. 45.Toriniwa, H., Komiya, T. 2006. Rapid detection and quangification of Japanese encephalitis virus by read-time reverse transcription loop-mediated isothermal amplification. *Microbiol Immunol*. 50:379-87. 46.Tsai, T. F. 2000. New initiatives for the control of Japanese encephalitis by vaccination minutes of a WHO/CVI meeting, Bangkok. Thailand. 13-15 October. *Vaccine* . 18:1-25. 47.Wang, I. K., Hsieh, S. Y., Chang, K. M., Wang, Y. C., Chu, A., Sahw, S. Y. 2006. A novel control scheme for inducing angiostatin-human IgG fusion protein production using recombinant CHO cells in an oscillating bioreactor. 121:418-28. 48.Vaughn, D. W., Hoke, Jr. CH. 1992. The epidemiology of Japanese encephalitis: Prospects for prevention. *Epidemiol Rev*. 14:197-221. 49.WHO. 1998. Requirements for the use of animal cells as in vitro substrates for the production of biologicals. *Biologicals*. 26:175-193. 50.World Health Organization. 1979. Technical information on Japanese encephalitis and guidelines for treatment, New Delhi: WHO Regional Office Southeast Asia. 51.Wu, S. C., Liu, C. C., Lian, W. C. 2004. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. *Vaccine*. 22:3858-64. 52.Wu, S. C.

- Huang, G. Y. L. 2002. Stationary and microcarrier cell culture processes for propagating Japanese encephalitis virus. *Biotechnol Pogr.* 18:124-128.
53. Wu, Y. C., Huang, Y. S., Chien, L. F., Lin, T. L., Yueh, Y. Y., Tseng, W. L., et al., 1999. The epidemiology of Japanese encephalitis on Taiwan during 1966-1997. *Am J Trop Med Hyg.* 61:78-84.
54. Yang, S. E., Pan, M. J., Tseng, H. F., Liao, M. Y. 2006. The efficacy of mouse-brain inactivated Nakayman strain Japanese encephalitis vaccine – Results from 30 years experience in Taiwan. *Vaccine.* 24:2669-2673.
55. Yoshimura, Y. 1962. Establishment of kidney cell strain of *Cercopithecus aethiops*, 14th Japan Tissue Culture Association, Tokyo.
56. Yoshimura, Y. 1963. Kawakita Y. Study of SV40 by tissue culture. A preparatory stage for in vitro cancer researcher. *Nippon Rinsho.* 21:1201-15.